NIH cuts halt 24-year program to prevent HIV/AIDS in adolescents

During Donald Trump's first term, he made it a goal to end the HIV epidemic in the U.S. by 2030. That priority has fallen by the wayside.

March 25, 2025 Check out STAT+

Sponsored By

Araya Diaz/Getty Images for AIDS Healthcare Foundation STAT+ | NIH cuts halt 24-year program to prevent HIV/AIDS in adolescents and young adults Adolescent Medicine Trials Network for HIV/AIDS Intervention has two major grants terminated by NIH. "Devastating," says one researcher. By Anil Oza STAT+ | Oz moves closer to role running Medicare, Medicaid on party-line vote Dr. Oz, a former heart surgeon and TV host, is closer to becoming CMS administrator after clearing a key Senate committee vote. By Tara Bannow 5 high-level CDC officials are leaving in the latest turmoil for the public health agency The CDC was rocked by five high-level departures on Tuesday in the latest turmoil for the nation's top public health agency. By Associated Press Mike Reddy for STAT STAT+ | Health insurers' rapid adoption of AI tools is outpacing regulators' ability to keep watch "Companies are full steam ahead and regulators are behind," says one expert as the health insurance industry starts using AI in almost every aspect of care. By Casey Ross Opinion: 23andMe's bankruptcy doesn't diminish its impact The era of patient-driven health care and genomic empowerment that 23andMe ignited is still in its infancy. By Michael Mina Trump nominates Republican once accused of mishandling taxpayer funds as HHS watchdog The Republican attorney was once accused of mishandling taxpayer funds and has a history of launching investigations against abortion clinics By Associated Press Jae C. Hong/AP Opinion: Cuts to Medicaid will set the U.S. back 35 years in dementia care "I'm scared … more so than I am of the disease I have," says a patient with dementia who depends on Medicaid-supported services. By Jason Karlawish STAT+ | Net prices for medicines inched up in last year's fourth quarter after falling a year ago, analysis finds Net prices are likely to decline this year due to the ongoing introduction of biosimilars, particularly for a class of medicines known as TNF. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser